How it is measured
The scale cannot tell visceral fat from any other weight. Trials measure it with DXA, a weak X-ray beam passed over the whole body that sorts each part into fat, bone mineral and lean tissue, or with MRI.1,3 The 2019 statement covers how these fats are measured, how they contribute to disease, how they respond to treatment, and lessons from a public health programme that targeted them. It notes that simple, clinically usable tools to follow them over time are still needed. It also calls for public health messages to focus on these fats as well as on body weight.2
What the scans showed
- Zepbound, SURMOUNT-1. 160 people were scanned at the start and at week 72, 124 on tirzepatide and 36 on placebo. Body weight fell by 21.3% on tirzepatide and 5.3% on placebo. Visceral fat fell by 40.1% on tirzepatide and 7.3% on placebo, against 33.9% and 8.2% for all fat. In kilograms, people on tirzepatide lost 15.9 kg of fat on average, against 3.6 kg on placebo. The waist shrank by 18.1 cm, about 7 inches, against 3.4 cm on placebo.1
- Wegovy, STEP 1. 140 people were scanned at the start and at week 68, 95 on semaglutide and 45 on placebo. Body weight fell by 15.0% on semaglutide, and visceral fat by 27.4%, against 19.3% for all fat.4
The two studies were separate, with different drugs, lengths and people, so the figures are not a head-to-head comparison. The same scans showed lean tissue falling too, by 10.9% on tirzepatide and 9.7% on semaglutide. Our page on muscle loss on a GLP-1 shows the full split of what the lost weight was made of.
Liver fat in people with diabetes
SURPASS-3 MRI measured fat by MRI in 296 adults with type 2 diabetes, comparing weekly tirzepatide with daily insulin degludec for 52 weeks. The participants had an HbA1c of 7.0 to 10.5%, a BMI of at least 25, had never used insulin, took metformin alone or with an SGLT2 inhibitor, and had a fatty liver index of at least 60. The study was open-label, ran at 45 centres in eight countries and was funded by Eli Lilly. MRI separated the fat inside the abdomen from abdominal subcutaneous adipose tissue, the fat under the skin. Liver fat started at an average of 15.71% of the liver. It fell by 8.09 percentage points on tirzepatide 10 or 15 mg, against 3.38 on insulin degludec. Tirzepatide also reduced the volumes of visceral fat and of abdominal fat under the skin. On tirzepatide, a larger fall in liver fat went with larger falls in visceral fat, in fat under the skin and in body weight.3
What it means in practice
For most people, a DXA or MRI scan is not part of treatment, and the trials scanned only a subset of their participants: 160 in SURMOUNT-1 and 140 in STEP 1. The waist is a simple measure the Zepbound study also reported: an average fall of 18.1 cm against 3.4 cm on placebo.1 A tape measure at the same spot each month shows a trend that the scale alone cannot.
Sources
- Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab 2025;27:2720-2729. doi:10.1111/dom.16275
- Neeland IJ, Ross R, Després JP, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol 2019;7:715-725. doi:10.1016/S2213-8587(19)30084-1
- Gastaldelli A, Cusi K, Fernández Landó L, et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol 2022;10:393-406. doi:10.1016/S2213-8587(22)00070-5
- Wilding J, Batterham R, Calanna S, et al. Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study. J Endocr Soc 2021;5(Suppl 1):A16-A17. PMC8089287
Related analyses
Muscle loss on Zepbound and Wegovy: how much of the weight lost is fat, and how much is muscle
How much protein to eat on Zepbound or Wegovy: the targets, calculated for your weight
Zepbound plateau: when weight loss slows, why, and what the trials show
What to eat on a GLP-1: the priorities of four medical societies, with a day you can build
Log your waist each month next to your weight; it tracks the fat the scale cannot separate.
Open Dose Insider